SS-31 and Mitochondrial Research: Mechanisms, Trials, and Limits
Published · Page updated
Bookmark this page
Save this article in your browser so you can find it again:
- Computer: Press Ctrl+D (Windows) or ⌘+D (Mac).
- iPhone or iPad: In Safari, tap Share, then Add Bookmark.
- Android: In Chrome, open the menu and tap the star.
Other browsers may use a different menu.
SS-31 is a research name for elamipretide, a synthetic peptide studied in mitochondrial biology and defined patient groups. Human findings depend on the condition and outcome studied. A negative primary result in mitochondrial myopathy and FDA's specific Forzinity approval for Barth syndrome are different pieces of evidence; neither validates a research vial. This guide separates those clinical findings from laboratory mechanisms. Molecular terminology
At a glance:
A laboratory mechanism does not guarantee a clinical benefit.
A randomized trial and an open-label extension have different limitations.
Approval of a particular medicine does not establish equivalence of a research vial.
Publisher disclosure: Bio Research LLC operates Bio Peptides Labs. This commercially interested, AI-assisted summary is not an independent scientific review. Source-access limits appear below.

What did the human SS-31 studies show?
The population, comparison and endpoint determine what each result can support. These findings should not be combined into one general benefit claim.
Evidence | Population and design | Result to retain |
|---|---|---|
MMPOWER-3 | 218 participants with primary mitochondrial myopathy; randomized placebo comparison | No significant improvement in the primary walking-distance or fatigue endpoints at 24 weeks |
SPIBA-201 randomized phase | 12 patients with Barth syndrome; blinded crossover comparison | No superiority on the primary walking-distance and fatigue endpoints |
SPIBA-201 extension | Open-label follow-up; ten entered, eight participated through 168 weeks | Knee-extensor strength increased during the extension; this was not a blinded placebo comparison |
Sources: MMPOWER-3 original report, FDA trial snapshot.
What do SS-31 and elamipretide refer to?
Research literature identifies elamipretide as SS-31, a synthetic four-amino-acid peptide. A 2020 mechanistic paper uses both names while investigating interactions within mitochondria. This establishes the terminology used in that paper, not the identity or equivalence of every product carrying either name. Chavez and colleagues, 2020
For material comparison, start with the exact chemical identity, formulation, and supporting lot documents. Keep those checks separate from whether a study's biological result is relevant to a research question.
What did cardiolipin experiments show?
Cardiolipin is a membrane lipid studied in mitochondrial function. Birk and colleagues investigated SS-31 using model membranes and mitochondrial preparations. They reported interactions with cardiolipin-containing membranes and effects on electron transfer, oxygen consumption, and production of ATP, a molecule cells use to transfer energy. These results describe the experimental conditions studied. 2014 study record, abstract at the authors' institution
These were controlled biochemical and mitochondrial experiments, not measurements of how energetic a person felt. The distinction matters because an assay of ATP production and a patient-reported symptom are not interchangeable endpoints.
A later study used biotin-labeled SS-31, a version with an added tag to help recover the material for analysis. Researchers chemically linked nearby molecules and analyzed them by mass spectrometry in isolated mitochondria. They identified interactions with proteins involved in energy production and other metabolic processes. This modified probe's interaction map is not a clinical efficacy result. Chavez and colleagues, 2020
Why include a clinical trial that missed its endpoints?
MMPOWER-3 was a randomized, double-blind, placebo-controlled trial involving 218 participants with primary mitochondrial myopathy, a group of genetic mitochondrial disorders affecting muscle function. At 24 weeks, elamipretide did not meet its primary endpoints for six-minute walking distance and total fatigue. Karaa and colleagues, 2023 — full text
Most adverse events were mild or moderate. However, adverse events led to treatment discontinuation in 8 of 109 elamipretide participants versus 2 of 109 placebo participants. Serious events occurred in both groups and were not deemed treatment-related. Stealth BioTherapeutics funded the trial. These qualifications matter; neither risk-free use nor safety of another formulation follows from the report. Safety results, Table 4, and funding disclosure — full text
This result belongs beside the mechanistic studies, not hidden behind them. A plausible mechanism does not guarantee that a tested intervention will improve the outcomes selected in a clinical trial. Conversely, a result in one defined population should not be restated as a universal result across every disease or research model.
Is SS-31 FDA approved?
Forzinity, an elamipretide medicine, has a specific FDA approval. A research vial labeled SS-31 does not acquire that approval. FDA approved Forzinity on September 19, 2025 to improve muscle strength in adults and children with Barth syndrome weighing at least 30 kg. Its accelerated approval rests on knee-extensor strength, an intermediate clinical endpoint. FDA prescribing information, sections 1 and 14
On November 11, 2026, FDA's ongoing accelerated-approval table still listed Forzinity's confirmatory requirement, PMR 4802-1, with an original projected completion date of March 31, 2030. The listing is not a report of completed confirmatory results; FDA also notes that entries may remain until labeling or Federal Register status updates. It does not establish the trial's present recruitment or progress. FDA ongoing-requirements table
The label identifies local reactions and serious hypersensitivity risks. Its safety information belongs to that medicine and clinical context. Approval does not establish a general anti-aging or energy-enhancement benefit, or authenticate a research-stock formulation. This article offers no equivalence claim or treatment recommendation. FDA label, sections 4–6
A practical way to read the next paper
Before carrying a conclusion into another context, write down:
The material: exact molecule, formulation, or modified probe.
The system: model membrane, isolated mitochondria, animal, or defined patient group.
The endpoint: binding, respiration, function, symptoms, or another stated measure.
The result: what changed, what did not, and what remains uncertain.
Then ask whether the proposed conclusion matches all four. This simple check helps prevent a mechanistic finding from becoming an unsupported product promise.
Our MOTS-C guide shows why endogenous human measurements require a different interpretation from administered-drug trials.
For separate material-documentation questions, use our COA, HPLC, and mass spectrometry guide and research peptide documentation checklist. Visit the research resource library for related guides.
Review method and source access
The original selected-study checks were completed September 27, 2026. The November 11 update rechecked FDA's trial snapshot, selected prescribing-information sections and ongoing accelerated-approval listing, plus the MMPOWER-3 abstract. The label reviewed is revised September 2025. The FDA table supplies a dated status check; no confirmatory trial dataset was reviewed. Earlier mechanistic-study and detailed safety checks retain their original source-access scope. No underlying datasets were independently reanalyzed, and this is not a complete clinical or regulatory review.
Bio Peptides Labs catalog materials are offered for lawful laboratory research only, not for human or veterinary use. No current inventory lot was tested or authenticated for this review.
The November 18, 2026 presentation update rechecked terminology in the 2020 paper, MMPOWER-3 primary results and safety passages, and FDA's original-approval snapshot. The earlier label and ongoing-requirement-table checks retain their November 11 scope; this update did not establish confirmatory-trial progress or reassess every later regulatory change.
References
On November 19, 2026, we rechecked MMPOWER-3's primary-result and safety passages and FDA's accelerated-approval table and 2025 prescribing information. This selected check does not establish confirmatory-trial progress or review every subsequent regulatory change.
